COMMENTARY

• As Japan’s Contract Drug Rep Ratio Rises, Expectations Grow for Specialist Talent and Flexible Workforce
  August 5, 2025

• Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
  July 28, 2025

• Taking on Solid Tumors - 9: ADCs Surge Ahead as TCEs Strive for a Foothold
  July 18, 2025

• FY2024 Sees Divergence in I/O Drug Sales, Keytruda Thrives while Rivals Face Pricing Headwinds
  July 4, 2025

• Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
  June 23, 2025

• Next Wave of ALS Drugs Emerging as Novartis, Nipro Enter Development Fray
  May 27, 2025

• Impact of US Drug Policy: President Trump Shaking the World of Pharma
  May 19, 2025

• New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
  May 8, 2025

• How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
  April 1, 2025

• Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
  March 24, 2025

• Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
  March 4, 2025

• New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
  February 10, 2025

• Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
  February 5, 2025

• Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
  January 27, 2025

• Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies
  January 9, 2025

• Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
  December 24, 2024

• Battle over Off-Year Price Revision Now Heading for Political Settlement
  December 13, 2024

• Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
  December 10, 2024

• Japan Needs Transparent Debates amid Growing “No” to Off-Year Revisions
  December 2, 2024

• MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
  November 27, 2024

ページ